In a report released today, Michael Yee from Jefferies maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...

S&P Global expects inflation to remain closer to 3.0% in 2025 as tariffs result in higher prices along the domestic supply ...

Sunshine Biopharma's K1.1 mRNA-LNP shows promise for HCC treatment in mice, while its 2024 revenue surged 45% to $34.9 million.

We recently published a list of Jim Cramer Says Wait A Little & Discusses These 11 Stocks. In this article, we are going to ...

The market has climbed by 5.8% over the past week, and is up 4.8% over the past year, with earnings expected to grow by 14% per annum in the coming years. Though the term 'penny stock' might sound ...

From stock decline to Hold rating, explore their growth strategy, client focus, and potential gains. Click for my MRVI update ...

Biotech leading the charge Until not so long ago, Moderna was a medium-sized biotech working in the niche space of mRNA. Prior to the pandemic, biotech had a market cap of around $6.5bn whereas ...

Morgan Stanley lowered the firm’s price target on Moderna (MRNA) to $32 from $39 and keeps an Equal Weight rating on the shares. The firm ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other stocks that Jim ... Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other ... newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and ...